

Welcome to RINVOQ Complete.

Resources designed around you.



You may have questions about RINVOQ.
That's why RINVOQ Complete is here to help you:

- Make sense of your insurance coverage
- Identify ways you may save on RINVOQ
- Fit RINVOQ into your life
- Get resources to track your progress

Your RINVOQ Complete Nurse Ambassador* is committed to helping you understand your treatment, answering your questions, and supporting you to achieve your personal goals. Your Nurse Ambassador will be there every step of the way, starting with finding ways to save on the cost of your prescription.

You've signed up for RINVOQ Complete. Here's what to do next:

1 Before you leave the office, ask your health care professional which specialty pharmacy your prescription is being sent to and write down its number below. This pharmacy will help fill your RINVOQ prescription and arrange delivery.

SPECIALTY PHARMACY: _____ PHONE: _____

2 Expect a call from your Nurse Ambassador within one business day (call may come from any area code). They'll help you navigate the prescription process, understand your insurance coverage, and help you identify ways you may be able to save on RINVOQ.

For questions, or if you have not yet connected with your Nurse Ambassador, please call **1.800.2RINVOQ** (1.800.274.6867).

*Ambassadors do not give medical advice and will direct you to your health care professional for any treatment-related questions, including further referrals.

For more information about AbbVie's privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
Please see Important Safety Information on reverse side.

Please see accompanying Full Prescribing Information, including the Medication Guide,
or visit www.rxabbvie.com/pdf/RINVOQ_pi.pdf

RINVOQ™ COMPLETE

 **RINVOQ™**
upadacitinib 15mg tablets

Use and Important Safety Information About RINVOQ™ (upadacitinib)¹

RINVOQ Use¹

RINVOQ™ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.

Important Safety Information About RINVOQ¹

What is the most important information I should know about RINVOQ?

RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.

- **Serious infections have happened in some people taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.** Your HCP should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You may be at higher risk of developing shingles (herpes zoster).
- **Lymphoma and other cancers, including skin cancers, can happen in people taking RINVOQ.**
- **Blood clots in the veins of the legs or lungs and arteries are possible in some people taking RINVOQ. This may be life-threatening and cause death.**
- Tears in the stomach or intestines and changes in certain laboratory tests can happen. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.

What should I tell my HCP BEFORE starting RINVOQ?

Tell your HCP if you:

- Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection such as:
 - Fever, sweating, or chills
 - Shortness of breath
 - Warm, red, or painful skin or sores on your body
 - Muscle aches
 - Feeling tired
 - Blood in phlegm
 - Diarrhea or stomach pain
 - Cough
 - Weight loss
 - Burning when urinating or urinating more often than normal
- Have TB or have been in close contact with someone with TB.
- Have had any type of cancer, hepatitis B or C, shingles (herpes zoster), or blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.
- Have other medical conditions including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.
- Live, have lived, or have traveled to parts of the country that increase your risk of getting certain kinds of fungal infections, such as the Ohio and Mississippi River valleys and the Southwest. If you are unsure if you've been to these areas, ask your HCP.

Please see accompanying Full Prescribing Information, including the Medication Guide, or visit www.rxabbvie.com/pdf/RINVOQ_pi.pdf

abbvie

- Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.
- Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant while taking RINVOQ and for at least 4 weeks after your last dose.
- Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. You should not breastfeed while taking RINVOQ and for at least 6 days after your last dose.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

- Medicines for fungal or bacterial infections
- Rifampicin or phenytoin
- Medicines that affect your immune system

Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.

What should I tell my HCP AFTER starting RINVOQ?

Tell your HCP right away if you:

- Have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.
- Have any signs or symptoms of blood clots during treatment with RINVOQ, including:
 - Swelling
 - Pain or tenderness in the leg
 - Sudden unexplained chest pain
 - Shortness of breath
- Have a fever or stomach-area pain that does not go away, and a change in your bowel habits.

What are the common side effects of RINVOQ?

These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.

RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Reference: 1. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc.



Enrollment and Prescription Form

All fields marked with an asterisk (*) are required.

The HCP and the patient or legally authorized person should fill out this form completely before leaving the office.

1 Patient's Information* - To be completed by patient or legally authorized person. Please print clearly.

First Name:	Last Name:	Date of Birth: / /	Gender: (check one) <input type="checkbox"/> M <input type="checkbox"/> F
Address:	City:	State: ZIP:	
Phone:	Email Address:		

Best Time to Call: Monday-Friday Anytime Morning Afternoon Evening Check here only if it is *not* okay to leave a messageWhen did you start on treatment? Not Yet Started 0-3 Months Ago 4-6 Months Ago 7-12 Months Ago Over 12 Months Ago

By enrolling, you may receive your own Nurse Ambassador. Ambassadors do not give medical advice and are trained to direct patients to their health care professionals for treatment-related advice, including further referrals. To learn about AbbVie's privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

I would like to receive news and updates about AbbVie's products, clinical trials, research opportunities, programs, and other information that may be of interest to me.

2 Insurance Information* Check box if your doctor's office will copy and attach insurance cards.

Beneficiary/Cardholder Name: _____	Prescription Insurance: _____
Medical Insurance: _____	Rx Group #: _____
Medical Insurance ID #: _____	Rx ID #: _____
Group #: _____	Rx Bin #: _____ Rx PCN #: _____

▼ FOR HEALTHCARE PROVIDER USE ONLY ▼

3 Diagnosis* Moderate to Severe Rheumatoid Arthritis (RA) (M05) Date of Diagnosis: ____/____/____

4 Clinical Information

Prior Therapies: _____

_____Concomitant Medications: _____

Allergies: _____
_____TB Test (Date): ____/____/____ Pos Neg
_____Fax any necessary clinical/office notes to the preferred Specialty Pharmacy only.
_____5 Prescriber Information I would like to receive a copy: Benefits Verification summary Prior Authorization formPrescriber's Name* (First, Last): _____

NPI #: _____Address*: _____
City*: _____ State*: _____ ZIP*: _____
Email: _____Office Phone*: _____
Office Contact Name: _____
Office Fax: _____

6 RINVOQ Complete Prescription* - required in the event a patient experiences an insurance delay or denial

Eligible patients must have (1) commercial insurance, (2) a valid Rx for RINVOQ, and (3) experienced a delay or denial in insurance determination. See program Terms and Conditions on reverse side. Please complete the full form as well as this section and sign below.

Prescription to be filled through an AbbVie-authorized pharmacy. I understand that faxing this form to RINVOQ Complete will result in an original copy being simultaneously transmitted to the AbbVie-authorized pharmacy under this section.

RINVOQ 15 mg
extended-release tablets
1 tablet (15 mg) p.o. once daily
Quantity: 30
Refills: _____

PRESCRIBER CERTIFICATION: I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed RINVOQ to the previously identified patient and that I provided the patient with a description of the RINVOQ Complete patient support program. I authorize RINVOQ Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy. I understand that no charge resource through RINVOQ Complete may support patients who are experiencing a delay in insurance coverage for RINVOQ until coverage is obtained, and I confirm that I will support the above-identified patient in seeking to secure such coverage as I deem appropriate. I certify that I will not seek reimbursement from any third party payor for any no charge product dispensed by an AbbVie authorized pharmacy.

Prescriber's Signature: (REQUIRED) _____ **Date:** ____/____/____

7 Sample dispensed: Yes No Dispense date: ____/____/____

8 Pharmacy Prescription - OPTIONAL - Fill out and sign corresponding prescription below.

Patient's preferred Specialty Pharmacy: _____ Check if faxed to Specialty Pharmacy

RINVOQ 15 mg
extended-release tablets
1 tablet (15 mg) p.o. once daily
Quantity: 30 90
Refills: _____

PRESCRIBER CERTIFICATION: I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed RINVOQ to the previously identified patient and that I provided the patient with a description of the RINVOQ Complete patient support program. I authorize RINVOQ Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan (if applicable).

Prescriber's Signature: (REQUIRED) _____ **Date:** ____/____/____

IMPORTANT INFORMATION: By submitting this form you are referring the above patient to AbbVie's patient support program to determine eligibility and receive support related to an AbbVie product. AbbVie, its affiliates, collaborators, and agents will use this information to provide the patient support and perform research and analytics, on a de-identified basis, for management of the program. For more information, visit www.abbvie.com/privacy.html. Please share this information with your patient.

Please see additional Important Safety Information, including **BOXED WARNING** on Serious Infections, Malignancy, and Thrombosis, on reverse side.

Please see accompanying full **Prescribing Information**.



Indication and Important Safety Information¹

INDICATION¹

RINVOQ™ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

Important Safety Information¹

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt RINVOQ until the infection is controlled.

Reported infections include:

- Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent infection prior to RINVOQ use.
- Invasive fungal infections, including cryptococcosis and pneumocystosis.
- Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

Carefully consider the risks and benefits of treatment with RINVOQ prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with RINVOQ, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCY

Lymphoma and other malignancies have been observed in patients treated with RINVOQ. Consider the risks and benefits of treatment with RINVOQ prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or in patients who develop a malignancy. NMSCs have been reported in patients treated with RINVOQ. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

THROMBOSIS

Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated with Janus kinase inhibitors used to treat inflammatory conditions. Many of these adverse events were serious and some resulted in death. Consider the risks and benefits prior to treating patients who may be at increased risk. Patients with symptoms of thrombosis should be promptly evaluated.

GASTROINTESTINAL PERFORATIONS

Gastrointestinal perforations have been reported in clinical studies with RINVOQ, although the role of JAK inhibition in these events is not known. In these studies, many patients with rheumatoid arthritis were receiving background therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). RINVOQ should be used with caution in patients who may be at increased risk for gastrointestinal perforation. Promptly evaluate patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.

LABORATORY ABNORMALITIES

Neutropenia

Treatment with RINVOQ was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000 cells/mm³). Treatment with RINVOQ is not recommended in patients with an ANC <1000 cells/mm³. Evaluate neutrophil counts at baseline and thereafter according to routine patient management.

Lymphopenia

Absolute lymphocyte counts (ALC) <500 cells/mm³ were reported in RINVOQ clinical studies. Treatment with RINVOQ is not recommended in patients with an ALC <500 cells/mm³. Evaluate at baseline and thereafter according to routine patient management.

Please see accompanying full Prescribing Information.

abbvie

©2019 AbbVie Inc. North Chicago, IL 60064 US-RNQR-190063 June 2019 Printed in U.S.A.

Anemia

Decreases in hemoglobin levels to <8 g/dL were reported in RINVOQ clinical studies. Treatment should not be initiated or should be interrupted in patients with hemoglobin levels <8 g/dL. Evaluate at baseline and thereafter according to routine patient management.

Lipids

Treatment with RINVOQ was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Manage patients according to clinical guidelines for the management of hyperlipidemia. Evaluate 12 weeks after initiation of treatment and thereafter according to the clinical guidelines for hyperlipidemia.

Liver enzyme elevations

Treatment with RINVOQ was associated with increased incidence of liver enzyme elevation compared to placebo. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are observed during routine patient management and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

EMBRYO-FETAL TOXICITY

Based on animal studies, RINVOQ may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RINVOQ and for 4 weeks after the final dose. Verify pregnancy status of females of reproductive potential prior to starting treatment with RINVOQ.

VACCINATION

Use of live, attenuated vaccines during, or immediately prior to, RINVOQ therapy is not recommended. Prior to initiating RINVOQ, patients should be brought up to date on all immunizations, including prophylactic zoster vaccinations, in agreement with current immunization guidelines.

LACTATION

There are no data on the presence of RINVOQ in human milk, the effects on the breastfed infant, or the effects on milk production. Available data in animals have shown the excretion of RINVOQ in milk. Advise patients that breastfeeding is not recommended during treatment with RINVOQ and for 6 days after the last dose.

HEPATIC IMPAIRMENT

RINVOQ is not recommended in patients with severe hepatic impairment.

ADVERSE REACTIONS

The most common adverse reactions in RINVOQ clinical trials ($\geq 1\%$) were: upper respiratory tract infection, nausea, cough, and pyrexia.

RINVOQ Complete Prescription Terms and Conditions

Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria.

Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ™ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient's insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

Reference: 1. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc.

